http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109776543-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_157f6ea8a2b996328769d9b5e934655f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcaa03b795cd8da869d58e8f28bf52e5
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
filingDate 2017-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6765936b94749a4e7c5c1ec15ff94fac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1278857aaadd78ad0fc917b84d9fd08a
publicationDate 2019-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-109776543-A
titleOfInvention Ibrutinib salt, its crystal, preparation method, pharmaceutical composition and application
abstract The invention discloses ibrutinib salt, its crystal, preparation method, pharmaceutical composition and application. The crystal of the ibrutinib salt has the structure shown in formula (I), wherein X is HCl, HBr or benzoic acid. The preparation method includes the following steps: in an organic solvent, ibrutinib and X are mixed, heated to a temperature of 40-130° C., completely dissolved, and cooled for crystallization. The crystals of the three salts of ibrutinib disclosed in the present invention are all new crystal forms, have excellent solubility, thermal stability, and greatly improved hygroscopicity, greatly improving the solubility and biological properties of ibrutinib Utilization, and the preparation method of the crystal is simple, suitable for large-scale industrial production, and has a good industrial application prospect.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106995445-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106995445-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110317203-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110317203-B
priorityDate 2017-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016160604-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016050422-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016156127-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18373917
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419484158
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24821094
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86754248
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451679761
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538408
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419557048
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID7909
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419513958
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419589583
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID242
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538410
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID180
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID702
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537701
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID260
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559198
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450922407
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8857
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419509191
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57252245
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411746874
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID243
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536243
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3776

Total number of triples: 49.